Entries by PR Newswire


New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line treatment setting.

First Blood Test to Diagnose Bipolar Disorder

A team involving researchers from Alcediag, Montpellier University Hospital, Les Toises Psychiatry Centre in Lausanne and Professor David J. Kupfer from the University of Pittsburgh identified and validated a combination of blood biomarkers specific to bipolar disorder. These results, recently published in the leading scientific journal Nature, have led to the development of the first diagnostic blood test for this disorder that affects more than 60 million people worldwide.

, ,

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina

Astellas Pharma Inc. President and CEO Kenji Yasukawa, Ph.D., today announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C. The facility will allow Astellas Pharma to expand the company’s resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope.


Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer

Cytovia Therapeutics LLC, a global biotechnology company focused on empowering natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that Luca Scavo, CPA, MBA has been appointed as Chief Financial Officer and James Priour, MBA has been appointed as Chief Product Officer, both effective immediately.

Evoke and Ashfield Health join forces to form new agile global platform

Today, Evoke announces the integration of Ashfield Health marketing and communications agencies to form a new global healthcare brand, experience and communications platform, purpose-built to make health more human. The combination of two leading global healthcare organizations in one agile platform under the Evoke name creates one of the industry’s deepest and most dynamic marketing and communications offerings.

EVERSANA and Limitless Minds Advance Pharmaceutical Sales Performance with New Cognitive & Behavioral Training Solution

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and Limitless Minds, a business and wellness coaching firm founded by professional athlete Russell Wilson and co-founders Trevor Moawad, Harrison Wilson and DJ Eidson, announced the launch of an integrated learning and performance solution for life sciences professionals.